Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Teucrium Corn Fund (CORN) vs Pfizer Inc (PFE) Price & Performance

Teucrium Corn FundTrade
Pfizer IncTrade

Price performance (Past 24H)

Key statistics

Teucrium Corn Fund vs Pfizer Inc — how do they compare? Teucrium Corn Fund trades at $17.56, while Pfizer Inc trades at $26.67 (market cap $154.18B). The key difference: Pfizer Inc pays a 6.36% dividend while Teucrium Corn Fund pays none, and Pfizer Inc is trading nearer its 52-week high, Teucrium Corn Fund nearer its low. Which is the better fit depends on your goals.

CORNPFE
Sector
Commodities - Metals/AgricultureHealth
52-Week High
$19.12$28.56
52-Week Low
$16.46$23.60
Market Cap
$154.18B
Volume
29,869,932
Enterprise Value
$205.67B
Dividend Yield
6.36%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Teucrium Corn Fund

CORN trades at $17.64, up 0.17% for the day, with technical indicators showing a bearish bias from moving averages despite a neutral oscillator stance and oversold short-term RSI. Recent news highlights strong performance in agricultural ETFs, with CORN returning 9.7% over the past month, driven by inflation trends and geopolitical tensions affecting commodity markets.

The outlook is mixed; positive momentum from commodity strength offers upside, but bearish technicals and reliance on volatile agricultural markets pose risks. Investors should weigh near-term commodity tailwinds against the absence of fundamental financial data and broader market sentiment shifts.

Pfizer Inc

Pfizer (PFE) trades at $26.74, up 2.06% today, with a bullish technical signal from moving averages and a consensus analyst price target of $27.86. Recent quarters show consistent earnings beats, though revenue has moderated from pandemic peaks. The company maintains a strong cash position of $20.48 billion (2024) and a dividend yield supported by a $0.43 per share payout. Key developments include a focus on obesity and oncology pipelines, with several catalysts expected in 2026.

The outlook balances a stable dividend and pipeline potential against post-COVID revenue normalization and patent cliff risks. Near-term upside exists if pipeline catalysts materialize, but investors face headwinds from competitive pressures and projected net income margin compression to 6.8% in 2026. The stock's valuation at a P/E of 35.21 appears elevated relative to earnings growth, warranting caution despite technical strength.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Teucrium Corn Fund

CORN is a commodity ETF that provides exposure to the price of corn futures. It uses a laddered investment strategy across multiple benchmark contracts to help minimize the impact of contango and roll costs in the agricultural market.

Read more on CORN

About Pfizer Inc

Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.

Read more on PFE